Medicamen Biotech Limited
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-… Read more
Medicamen Biotech Limited (MEDICAMEQ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: 0.018x
Based on the latest financial reports, Medicamen Biotech Limited (MEDICAMEQ) has a cash flow conversion efficiency ratio of 0.018x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹36.46 Million) by net assets (₹2.00 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medicamen Biotech Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Medicamen Biotech Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Medicamen Biotech Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medicamen Biotech Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Entertainment Network (India) Limited
NSE:ENIL
|
-0.016x |
|
Sekuro Plastik Ambalaj Sanayi AS
IS:SEKUR
|
-0.167x |
|
Eagle Pharmaceuticals Inc
PINK:EGRX
|
0.000x |
|
ROK Resources Inc.
OTCQB:ROKRF
|
0.058x |
|
T-Flex Techvest PCB Co., Ltd.
TWO:3276
|
0.055x |
|
Black Dragon Gold Corp
AU:BDG
|
0.232x |
|
IokCompany Co. Ltd
KQ:078860
|
-0.020x |
|
Higgstec
TWO:5220
|
0.008x |
Annual Cash Flow Conversion Efficiency for Medicamen Biotech Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Medicamen Biotech Limited from 2006 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹2.13 Billion | ₹-98.59 Million | -0.046x | -42.21% |
| 2024-03-31 | ₹2.07 Billion | ₹-67.44 Million | -0.033x | -0.14% |
| 2023-03-31 | ₹1.93 Billion | ₹-62.93 Million | -0.033x | -215.97% |
| 2022-03-31 | ₹1.46 Billion | ₹41.09 Million | 0.028x | -70.81% |
| 2021-03-31 | ₹1.33 Billion | ₹127.72 Million | 0.096x | -9.00% |
| 2020-03-31 | ₹1.21 Billion | ₹128.02 Million | 0.106x | +112.74% |
| 2019-03-31 | ₹866.34 Million | ₹43.01 Million | 0.050x | +167.91% |
| 2018-03-31 | ₹746.08 Million | ₹-54.54 Million | -0.073x | -154.50% |
| 2017-03-31 | ₹267.81 Million | ₹35.92 Million | 0.134x | -61.29% |
| 2016-03-31 | ₹179.09 Million | ₹62.06 Million | 0.347x | +281.86% |
| 2015-03-31 | ₹171.85 Million | ₹-32.74 Million | -0.191x | -161.32% |
| 2014-03-31 | ₹165.38 Million | ₹51.39 Million | 0.311x | +410.42% |
| 2013-03-31 | ₹157.17 Million | ₹-15.73 Million | -0.100x | +42.34% |
| 2012-03-31 | ₹201.01 Million | ₹-34.90 Million | -0.174x | -131.21% |
| 2011-03-31 | ₹204.12 Million | ₹113.52 Million | 0.556x | +722.44% |
| 2010-03-31 | ₹162.61 Million | ₹11.00 Million | 0.068x | -89.45% |
| 2009-03-31 | ₹129.60 Million | ₹83.07 Million | 0.641x | +227.09% |
| 2008-03-31 | ₹115.83 Million | ₹22.70 Million | 0.196x | +662.67% |
| 2007-03-31 | ₹100.73 Million | ₹2.59 Million | 0.026x | -91.54% |
| 2006-03-31 | ₹85.67 Million | ₹26.02 Million | 0.304x | -- |